In its latest quarter ending March 31, 2026, XOMA Royalty Corporation showcased solid operational momentum, registering net income of $4.5 million and bolstering cash reserves to $138.7 million. The company’s royalty aggregator model, which centers on acquiring milestone and royalty payment rights from diverse pharmaceutical assets, continues to generate revenue streams with limited operational risk. XOMA's business hinges on well-capitalized licensees advancing drug candidates across clinical phases, with revenue recognized using effective interest rate and units-of-revenue methods. The impending merger agreement with Ligand Pharmaceuticals represents a strategic inflection point. However, dependency on partner commercialization success alongside regulatory and clinical development risks remains key watchpoints.